Morphea: Evidence-based recommendations for treatment

Fett, Nicole

doi:10.4103/0378-6323.93628

Cited by 27 publications

(28 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…autoimmune thyroiditis, alopecia areata, vitiligo, diabetes mellitus type I, and ulcerative enteritis [5][6][7]. The environmental factors such as Borrelia burgdorferi, injuries, radiation and drugs (β-blockers, bleomycin, D-penicillamine, bromocriptine) are also implicated in the etiopathogenesis of LS [2,8,9].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma

Budzyńska-Włodarczyk

Michalska-Jakubus²,

Kowal³

et al. 2016

pdia

View full text Add to dashboard Cite

A b s t r a c t Introduction: Localized scleroderma is an autoimmune disease primarily affecting the skin. The cause of disease remains unexplained although environmental factors are implicated, which are likely to be responsible for activation of the endothelium and subsequent inflammation leading to excessive synthesis of collagen and extracellular matrix components. Aim: To determine concentrations of interleukin (IL)-27, transforming growth factor (TGF)-β1, TGF-β2, IL-6, and sIL-6R in patients with localized scleroderma compared to controls and to assess the relations between their levels and laboratory markers. Material and methods: The study encompassed 17 females with localized scleroderma (aged 25-67). The control group consisted of 30 age-matched healthy women. The blood was sampled from the basilic vein. Serum levels of cytokines were determined using ELISA. Results: The TGF-β2 levels were found to be significantly lower in patients with localized scleroderma compared to controls. Concentrations of TGF-β1 were decreased in scleroderma patients when compared to controls but without statistical significance. There were no significant differences in serum IL-6, sIL-6R and IL-27 levels between patients and the control group; however, we found a significant positive correlation between the level of sIL-6 and ESR among subjects with localized scleroderma. Conclusions: The findings of decreased serum levels of TGF-β1 and TGF-β2 in patients with localized scleroderma demonstrate a possible association of these cytokines with pathogenesis of the disease. The results suggest also that sIL-6R is likely to be involved in inflammation in patients with localized scleroderma.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma

Budzyńska-Włodarczyk

Michalska-Jakubus²,

Kowal³

et al. 2016

pdia

View full text Add to dashboard Cite

show abstract

“…El tratamiento está dirigido, tanto a la fase activa, con el objetivo de estabilizar el tamaño de las lesiones actuales, como a la fase inactiva, para prevenir futuras cicatrices y contracturas 38 .…”

Section: Tratamientounclassified

“…Se debe iniciar con tacrolimus tópico, dos veces al día. Si después de ocho semanas no se observa mejoría, se puede cambiar el tratamiento por cualquiera de las siguientes opciones: fototerapia limitada a la lesión (UVA1, PUVA en baños, UVB de banda estrecha), calcipotrieno ocluido dos veces al día, calcipotrieno más dipropionato betametasona, una o dos veces al día, o imiquimod tópico, tres veces por semana 34,38 .…”

Section: Esquemas De Tratamiento Que Recomienda La Literaturaunclassified

Morfea o esclerodermia localizada

Gaviria¹,

Jiménez²,

Gutiérrez³

2014

rev. asoc. colomb. dermatol. cir. dematol.

View full text Add to dashboard Cite

La esclerodermia es un término que se deriva de las palabras griegas skleros (duro o endurecido) y dermis (piel). La esclerodermia localizada, también conocida con el nombre de morfea, es un trastorno fibrosante raro que afecta la piel y los tejidos adyacentes, y se limita casi de manera exclusiva a los tejidos derivados del mesodermo. La patogénesis no está dilucidada por completo, pero se sabe que es una enfermedad autoinmunitaria en la cual existen múltiples factores que contribuyen a aumentar las citocinas proinflamatorias, lo cual conduce a un desequilibrio entre la producción y la destrucción del colágeno, que finalmente va a favorecer la fibrosis que caracteriza a esta enfermedad. Aunque la morfea es un trastorno localizado de la piel, los pacientes con esta enfermedad comúnmente pueden tener síntomas sistémicos, como malestar general, fatiga, artralgias y mialgias, así como autoanticuerpos circulantes positivos. Se diferencia principalmente de la esclerosis difusa (esclerosis sistémica) por la ausencia de esclerodactilia, fenómeno de Raynaud, cambios capilares del lecho ungular y compromiso de órganos internos.

show abstract

“…Currently, the evidence-based treatment protocol for treatment of morphea in various scenarios is as follows:[50]…”

Section: Introductionmentioning

confidence: 99%

Current treatment strategies: Collagen vascular diseases in children

Palit

Inamadar

2012

Indian J Dermatol

View full text Add to dashboard Cite

Of the various collagen vascular diseases seen in pediatric age group, discoid lupus erythematosus, systemic lupus erythematosus, neonatal lupus erythematosus, juvenile dermatomyositis and childhood scleroderma are common and of practical importance to clinicians. Various treatment modalities of these conditions have been discussed at length. Of these, some are conventional and routine,while others are used in challenging situations of these diseases. Autologous stem cell transplant, biological therapies, intravenous immunoglobulin and narrow band ultraviolet B are among the latest therapeutic options for these difficult-to-treat conditions in children.

show abstract

Morphea: Evidence-based recommendations for treatment

Cited by 27 publications

References 42 publications

Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma

Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma

Morfea o esclerodermia localizada

Current treatment strategies: Collagen vascular diseases in children

Contact Info

Product

Resources

About